In recent years, there has been a noticeable increase in the level and incidence of blood lipid abnormalities in China.
“Many patients have the habit of measuring blood pressure and blood sugar, but they do not pay enough attention to ‘bad cholesterol’, which is a key target.” It was pointed out that “bad cholesterol” refers to low-density lipoprotein cholesterol (LDL-C) in the blood lipids, the “culprit” causing hyperlipidemia. It is also a significant risk factor for causing myocardial infarction, ischemic stroke, and other atherosclerotic cardiovascular diseases (ASCVD). Therefore, lowering LDL-C levels can significantly reduce the incidence and death risk of ASCVD. Effective control of blood lipid abnormalities is of great significance for the prevention and control of ASCVD in China, and strengthening the prevention and treatment of hyperlipidemia is important for public health.
At the 19th Eastern Cardiology Conference (OCC2025), experts emphasized the importance of managing blood lipids through “precise stratification, targeted intervention, and moving the barrier forward” in a health interview focused on managing heart and lipid health, conveying the importance of lipid management to the public and medical community
